Anti-PROX1
Keywords:
Retina, Regeneration, Müller glial cells, Anti-PROX1 therapy, VisionAbstract
The text discusses a scientific breakthrough developed by KAIST researchers in the field of retinal regeneration. It explains that millions of people suffer from retinal diseases that can lead to vision loss, and that there is currently no effective therapy to restore sight once it has been lost. The research suggests that, unlike fish, mammals cannot naturally regenerate the retina because the protein Prox1 accumulates in Müller glial cells and blocks regeneration. By inhibiting this protein through Anti-PROX1 therapy, these cells could be reprogrammed to produce new retinal cells, including photoreceptors and retinal ganglion cells, which are affected in diseases such as retinitis pigmentosa and glaucoma.
The described artwork represents this advance through a pair of eyes looking at a screen displaying the message “Anti-PROX1,” with a blue-toned fish in the background symbolizing natural retinal regeneration. Finally, the text reflects on the everyday impact of visual problems and presents the possibility of recovering sight without surgery or glasses as a shared hope for millions of people.
Downloads
References
Lee, E. J., Kim, M., Park, S., et al. (2025). Restauración del potencial regenerativo retiniano de la glía de Müller mediante la interrupción de la transferencia intercelular de Prox1. Nature Communications, 16 (1) 2928. https://doi.org/10.1038/s41467-025-58290-8
Meza Capcha, E. (2025, abril 4). Primer fármaco capaz de restaurar la visión mediante regeneración de células retinales. Infobae. https://www.infobae.com/peru/2025/04/04/primer-farmaco-capaz-de-restaurar-la-vision-mediante-regeneracion-de-celulas-retinales/#:~:text=C%C3%B3mo%20el%20f%C3%A1rmaco%20desarrollado%20por,enfermedades%20degenerativas%20de%20la%20retina
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2026 SIBIUAS Revista de la Dirección General de Bibliotecas

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
